AKD advises on the sale of CliniChain Holding B.V. to ADDvise Group AB

December 8, 2022

AKD has assisted the founders and management of CliniChain B.V. with the sale of their equity stake to ADDvise Group AB. Headed by Carlos Pita Cao, the AKD team consisted of David Molenaar, Ludo Luijks, Maud Plattel, Remco Bosveld, Niels Hagelstein and Ronald van der Stap.

Swedish ADDvise Group AB (Nasdaq First North Premier Growth Market SE0007464862) has entered into a share purchase agreement with the shareholders of CliniChain Holding B.V. (“CliniChain”) regarding the acquisition of all outstanding shares of CliniChain, a fast-growing international med-tech equipment provider for clinical studies headquartered in the Netherlands. The company offers tailored rental and purchase solutions of med-tech equipment that are adapted to each phase of clinical studies. CliniChain’s customers include contract research organisations, biotech and pharmaceutical companies.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product-wise. ADDvise Group’s shares are listed on Nasdaq First North Premier Growth Market and Mangold Fondkommission AB is the Company's Certified Adviser.

The full press release can be found here.